TransCode Therapeutics Inc (NASDAQ:RNAZ) has a beta value of 0.57 and has seen 0.56 million shares traded in the recent trading session. The company, currently valued at $2.58M, closed the recent trade at $3.70 per share which meant it lost -$2.62 on the day or -41.41% during that session. The RNAZ stock price is -7035.14% off its 52-week high price of $264.00 and -70.54% below the 52-week low of $6.31. If we look at the company’s 10-day average daily trading volume, we find that it stood at 38460.0 shares traded. The 3-month trading volume is 47.66K shares.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Sporting -41.41% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RNAZ stock price touched $3.70 or saw a rise of 53.46%. Year-to-date, TransCode Therapeutics Inc shares have moved -98.30%, while the 5-day performance has seen it change -53.11%. Over the past 30 days, the shares of TransCode Therapeutics Inc (NASDAQ:RNAZ) have changed -66.02%. Short interest in the company has seen 0.74 million shares shorted with days to cover at 0.5.
TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Figures show that TransCode Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -89.01% over the past 6 months, with this year growth rate of 98.22%, compared to 16.80% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
1 analysts offering their estimates for the company have set an average revenue estimate of 300k for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -28.81% over the past 5 years.
RNAZ Dividends
TransCode Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
Insiders own 0.01% of the company shares, while shares held by institutions stand at 1.99% with a share float percentage of 1.99%. Investors are also buoyed by the number of investors in a company, with TransCode Therapeutics Inc having a total of 11.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund. As of Oct 31, 2024, the former fund manager holds about 0.42% shares in the company for having 2.91 shares of worth $10519.0 while later fund manager owns 1.18 shares of worth $4271.0 as of Oct 31, 2024, which makes it owner of about 0.17% of company’s outstanding stock.
